ArticleThoracic cancer2025
Identifying Risk Factors Associated With False-Negative Results in US-Guided Percutaneous Transthoracic Needle Lung Biopsy of Subpleural Pulmonary Lesions.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aims to investigate the factors influencing false-negative results in ultrasound-guided percutaneous transthoracic needle lung biopsy results (US-PTLB). MATERIALS AND
methodsThis ambispective cohort study included patients with subpleural pulmonary lesions who underwent US-PTLB with benign pathological findings between April 2017 and June 2022 (retrospective cohort) and between July 2022 and October 2022 (prospective cohort). In the retrospective cohort, comparative and logistic regression analyses were performed to identify independent risk factors for false-negative biopsy results. Stratified analyses based on these risk factors were performed in the prospective cohort.
resultsThe retrospective cohort included 1747 (true-negative: false-negative, 1321:426) patients with negative biopsy results, which were analyzed by comparative and logistic regression analyses, and the results demonstrated that advanced age (> 56 years) (OR = 1.08, 95% CI: 1.07-1.09), small-sized lesions (< 3 cm) (OR = 1.80, 95% CI: 1.38-2.34), lesions with necrosis (OR = 3.00, 95% CI: 2.29-3.92), contrast-enhanced ultrasound (CEUS) showing hyper-enhancement (OR = 5.87, 95% CI: 4.09-8.42) or iso-enhancement (OR = 2.81, 95% CI: 2.05-3.83), and the presence of hemoptysis (OR = 11.82, 95% CI: 5.16-27.08) or pneumothorax (OR = 7.90, 95% CI: 2.89-21.58) during the puncture were independent predictors of false-negative US-PTLB results. The results of stratified analyses in the prospective cohort were consistent with the retrospective cohort.
conclusionRisk factors associated with false-negative results included advanced age (> 56 years), small-sized lesion (< 3 cm), presence of necrosis in the lesion, CEUS showing hyper-enhancement or iso-enhancement of the lesion, and hemoptysis or pneumothorax during puncture.
trial registrationNumber: ChiCTR2000029749.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.